Study on cannabis chemical as a treatment for pancreatic cancer may have ‘major impact,’ Harvard researcher says
Pancreatic cancer makes up just 3 percent of all cancers in America. But with a one-year survival rate of just 20 percent (and five-year survival rate of less than 8), it’s predicted to be the second leading cause of cancer-related death by 2020.
Headlines about the illness, as a result, tend to be discouraging. But this month scientists from Harvard University’s Dana-Farber Cancer Institute have released some much-needed good news. In their study, published in the journal Frontiers of Oncology on July 23, the researchers revealed that a chemical found in cannabis has demonstrated “significant therapy potential” in treatment of pancreatic cancer.
Stories you may be interested in
European Parliament Passes Cannabis Resolution, Joins WHO In Supporting Medical Marijuana
Following reports about the World Health Organization (WHO) recommending a rescheduling of cannabis and several of its key components under international drug treaties, the European Parliament voted on Wednesday on a resolution that would help advance medical cannabis in the countries that form the European Union. Read the full story here.
Read More 
Updated Arfinn Med Scheduler
As your practice begins to grow, it’s important that your booking system is able to keep up. That’s why Arfinn Med has just released, in its newest update, the multi-view scheduling and booking platform. This allows you and/or your staff the ability to customize appointment types, hours of availability, display name, and confirmation emails for…
Read More 
Medical Marijuana Faces Acceptance Barrier by Hesitant Medical Schools
A new study shows a growing interest by university pharmacy programs in teaching about medical marijuana in their curriculum, while medical schools seem to lag behind. Sixty-two percent of U.S. pharmacy school respondents queried in a new survey said they included medical marijuana in their doctorate of pharmacy curriculum. That’s according to a nine-page study co-authored by…
Read More 
THC vs. CBD: What You Need to Know
With the rising demand of natural medicines, medical marijuana compounds THC and CBD are starting to make a name for themselves more than ever before. These two compounds have a wide range of health benefits, making it understandable why patients and physicians would be interested in this alternative treatment option. Although these two compounds are…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More 
More Treatment Options, Better Patient Outcomes
As more states start to pass medical marijuana legislation, patients benefit from having more options available to them regarding their treatment. In fact, a recent study from Columbia University’s Irving Medical Center found that, “States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana…
Read More